Cumberland Pharmaceuticals Inc. — Q3 2023 Form 10-Q Summary
Business context and reporting period
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing branded prescription products in hospital acute care, gastroenterology and oncology. The company markets products primarily in the United States and uses international partners for selected territories. This unaudited Form 10-Q covers the three and nine months ended September 30, 2023, compared with the corresponding 2022 periods.
Key financial metrics
| Metric | Three months ended September 30, 2023 | Three months ended September 30, 2022 | Nine months ended September 30, 2023 | Nine months ended September 30, 2022 |
|---|---|---|---|---|
| Net revenues | $10.1 million | $11.4 million | $30.2 million | $32.9 million |
| Gross profit | $8.3 million | $9.2 million | $25.7 million | $26.4 million |
| Gross margin | 82.5% | 80.5% | 85.0% | 80.3% |
| Operating loss | $(1.9) million | $(0.3) million | $(3.4) million | $(3.4) million |
| Net income (loss) attributable to common shareholders | $(1.0) million | $(0.4) million | $15,086 | $(3.1) million |
| Operating cash flow | Not separately provided for the quarter | Not separately provided for the quarter | $5.1 million | $4.8 million |
Third-quarter operating margin was approximately negative 18.5%, compared with negative 2.5% in the prior-year quarter. Nine-month operating margin was approximately negative 11.2%, broadly consistent with the prior-year period. Third-quarter net margin attributable to common shareholders was approximately negative 10.4%; the nine-month result was approximately breakeven because of unusual other income.
- Cash and cash equivalents were $18.5 million at September 30, 2023, compared with $19.8 million at December 31, 2022.
- Working capital was $14.4 million, down from $17.3 million, and the current ratio was 1.5 versus 1.6.
- The revolving credit facility had $12.9 million outstanding and approximately $7.1 million of availability at September 30, 2023.
- The company generated $5.1 million of operating cash flow, used $0.4 million in investing activities and used $5.9 million in financing activities, resulting in a $1.3 million decrease in cash.
- Total lease liabilities were $5.7 million. The company had no off-balance-sheet arrangements.
Material changes versus the prior comparable period
- Third-quarter revenue declined $1.3 million, or approximately 11.6%; nine-month revenue declined $2.7 million, or approximately 8.2%.
- Sancuso revenue declined $2.0 million in the quarter and $5.0 million for the nine months, primarily due to managed-care rebates, product returns and other sales deductions.
- Vibativ revenue increased $0.9 million in the quarter and $0.8 million for the nine months, supported by commercial initiatives and lower product returns.
- Kristalose revenue was approximately flat in the quarter but increased $0.9 million for the nine months. Caldolor revenue increased $0.2 million in both the quarter and nine-month period, primarily reflecting higher international shipments.
- Vaprisol had no third-quarter revenue and no commercial revenue for the nine-month period because the company remains out of inventory while transitioning to a new manufacturer. Omeclamox-Pak also lacked commercial inventory, and RediTrex distribution ended June 30, 2023.
- Cost of products sold decreased $0.5 million in the quarter and $1.9 million for the nine months due to lower-cost inventory and fewer inventory write-downs.
- Selling and marketing expense increased $0.6 million in the quarter and $0.4 million for the nine months. Research and development expense decreased $0.7 million for the nine months, primarily because of lower FDA fees, while general and administrative expense increased $0.5 million.
- Amortization expense declined $0.3 million in the quarter and $1.0 million for the nine months, primarily reflecting changes in the estimated useful life and valuation of Sancuso.
Guidance, outlook, management commentary, risks and unusual items
- Management stated that existing working capital, internally generated cash flow and the revolving credit facility are expected to be adequate to finance internal growth, business development initiatives and capital expenditures for the foreseeable future. No specific revenue or earnings guidance was provided.
- Management is pursuing growth through existing-brand expansion, selective acquisitions, international partnerships and development of the ifetroban pipeline. Phase II programs are underway for systemic sclerosis and Duchenne muscular dystrophy, and the company is initiating a Phase II idiopathic pulmonary fibrosis study.
- The company expects Caldolor may qualify for separate Medicare reimbursement under the NOPAIN Act for eligible products furnished beginning January 1, 2025. CMS implementation rules and eligibility determinations remain pending.
- The new Pinnacle Bank revolving facility was entered into on September 5, 2023. It provides an initial borrowing capacity of up to $20 million, potentially increasing to $25 million, expires October 1, 2026, bears interest at Term SOFR plus 2.75% under the applicable pricing, and is secured by substantially all company assets. Borrowings are subject to a Funded Debt Ratio covenant.
- Other income for the first nine months included approximately $2.8 million of FDA fee refunds, $0.5 million from a manufacturing-dispute settlement and $0.3 million of insurance proceeds. These items materially improved the nine-month earnings comparison.
- The company paid a $200,000 SEC civil penalty in September 2023 relating to late Section 16 ownership filings and inadequate related disclosure. Management does not expect the matter to materially affect operations.
- Key operating risks include product supply interruptions, FDA and manufacturing-site approvals, product returns and rebates, clinical and regulatory development risk, acquisition and integration risk, dependence on third-party manufacturers, rising interest rates and inflation. Vaprisol and Omeclamox-Pak supply remain unresolved.
- The company had approximately $53.2 million of federal net operating loss carryforwards and expects to pay minimal income taxes during 2023 and beyond on taxable operating income, subject to continued availability and utilization of those carryforwards.
Important facts for investors to verify
- Whether Sancuso revenue and managed-care deductions stabilize following completion of the product transition and expansion of the oncology sales force.
- The timing of FDA resolution and commercial supply for Vaprisol, including the status of the new manufacturer and interim compounded product.
- Whether Omeclamox-Pak packaging operations resume and whether alternative packaging arrangements are secured.
- Progress, enrollment, funding and results of the ifetroban Phase II programs, including the planned idiopathic pulmonary fibrosis trial.
- CMS’s final NOPAIN Act rules and whether Caldolor receives separate Medicare reimbursement beginning in 2025.
- Compliance with the new credit facility’s Funded Debt Ratio covenant, interest-rate exposure and remaining borrowing availability.
- The sustainability of operating cash generation given declining revenue, continued operating losses and contingent royalty and milestone obligations.
- The extent to which FDA refunds, settlements and insurance proceeds affected nine-month 2023 profitability and are not recurring.